Neurocrine Biosciences shares are trading lower after the company reported worse-than-expected Q3 sales results. Following earnings, multiple firms lowered their respective price targets on the stock.

by Asad | Nov 2, 2021 | Uncategorized | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.